Musk Must Face Cave Rescuer Lawsuit Over ‘Pedo Guy’ Tweet
(Bloomberg) -- Elon Musk can't duck behind an “imaginative insult” defense to escape a lawsuit by a British cave rescuer who took offense at being called a “pedo guy" after he had ridiculed Musk's mini-submarine.
A federal judge in Los Angeles on Friday denied the Tesla Inc. chief executive officer's request to dismiss Vernon Unsworth's defamation complaint. The judge said a written ruling explaining his order will come later.
The spat with Unsworth erupted after the caver pooh poohed the mini-submarine Musk had built to assist in the rescue of a group of Thai boys that were trapped in a flooded cave last year. Unsworth said in a CNN interview that the mini-submarine, which wasn't used in the rescue, was a "p.r. stunt" and that Musk could "stick his submarine where it hurts."
Musk's tweeting habits, particularly regarding Tesla's business, have landed him in hot water with investors and the Securities and Exchange Commission. Under a settlement with the SEC last year, he's supposed to have the company oversee his Tesla-related tweets that could influence the market. A February tweet about 2019 Tesla deliveries prompted the SEC to go to court to accuse Musk of violating the agreement. Musk and the SEC on Friday agreed anew to settle the dispute.
John Hueston, a lawyer for Musk, didn't immediately respond to a request for comment on the ruling.
The case is Unsworth v. Musk, 18-cv-08048, U.S. District Court, Central District of California (Los Angeles).
To contact the reporter on this story: Edvard Pettersson in Los Angeles at epettersson@bloomberg.net
To contact the editors responsible for this story: Elizabeth Wollman at ewollman@bloomberg.net, Peter Blumberg
©2019 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.